Step Forward for Access to Off-Patent Medicines (New Zealand)
This article was originally published in PharmAsia News
Executive Summary
New Zealand's drug-funding agency, PHARMAC, has suggested a policy amendment designed to make off-patent medications more easily available to the public. If approved, the changes would offer more leeway for people who need medications not approved under a PHARMAC contract. Currently, PHARMAC, forms agreements with one pharmaceutical company to provide a medication to a particular market. By asking drug-makers to bid for exclusive access to these areas, PHARMAC has saved over $300 million on drug costs since 1998. Since the institution of these contracts, there have been some complaints by doctors and patients, claiming not all people respond to a particular drug-brand. In response to these concerns, PHARMAC will allow up to 1 percent of patients access to drugs not approved under the contract, provided they can present clinical evidence proving their need for a specific brand of drug. (Click here for more
You may also be interested in...
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.